69
Participants
Start Date
December 17, 2021
Primary Completion Date
July 21, 2026
Study Completion Date
October 31, 2026
metreleptin
Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
Placebo
Placebo
The Children's Hospital of Philadelphia, Philadelphia
Emory University, Atlanta
Flourish Boca Raton, Boca Raton
University of Alabama, Birmingham
Amryt Research Site, Endocrinology Research Associates Inc, Columbus
The Ohio State University Wexner Medical Center, Columbus
University of Michigan, Ann Arbor
Medical College of Wisconsin, Milwaukee
Mayo Clinic, Rochester
University of Missouri, Columbia
UT Southwestern Medical Center, Dallas
UC Davis, Sacramento
Massachusetts General Hospital, Boston
UZ Leuven, Leuven
Universitário Walter Cantídio, Fortaleza
Insight Centro de Pesquisas, Porto Alegre
Hospital das Clinicas FMRP-USP, Ribeirão Preto
Instituto Estadual de Diabetes e Endocrinologia (IEDE-RJ), Rio de Janeiro
Universidad Catolica, Santiago
Hadassah University Hospital - Ein Kerem, Jerusalem
Leids Universitair Medisch Centrum, Leiden
Radboud University Medical Centre Interne Geneeskund, Nijmegen
Uniwersyteckie Centrum Kliniczne, Katowice
SPZOZ Szpital Uniwersytecki w Krakowie, Krakow
University Clinical Hospital of Santiago de Compostela/Hospital Universitario, Santiago de Compostela
Nova Scotia Health, Halifax
Care Access Clinic, Sydney
Hamilton General Hospital- McMaster University, Hamilton
London Health Science Centre, London
Ecogene-21, Chicoutimi
Faculty of Medicine, Universite Laval, Québec
Lead Sponsor
Amryt Pharma
INDUSTRY